NVP022



NAME OF DRUG : NVP022

ALSO KNOWN AS : NVP022

LABORATORY : NeuroVivePharmaceuticalAB

STATUS AND ADVANCEMENT

Type of drug : mild mitochondrial protonophores

Clinical trials advancement : Preclinic

Estimated time to market : 136 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

HISTORY AND ANALYSIS

NVP022 targets the metabolic components of NASH by using mild, liver-targeted protonophores to increase energy expenditure, remove excess fat storage in the liver and thereby counteract the pathophysiological processes in NASH. NVP022 is NeuroVive’s second project for NASH, complementing the direct anti-fibrotic action of the company’s NV556 project.

Mitochondrial protonophores, such as dinitrophenol (DNP) have long been known to promote weight loss and impact markers of NASH in preclinical models. NeuroVive’s innovative compounds in the NVP022 project have been designed to have an overall improved therapeutic index and by specifically targeting these novel compounds to the liver they will ensure good safety and tolerability in treatment of NASH.

“Our project has received great interest, scoring in the top 10 per cent of abstracts. This reflects the high unmet medical need of NASH and interest in finding new treatment approaches of the disease processes. The discovery project NVP022 is based on NeuroVive’s core competence in mitochondrial energy regulation and the partner company Isomerase’s innovative chemistry capabilities, says Eskil Elmér, Chief Scientific Officer and VP of Discovery at NeuroVive.

The abstract "Preclinical analysis of liver-targeted, mild mitochondrial protonophores for treatment of non-alcoholic fatty liver disease and steatohepatitis" has been selected as a Presidential Poster of Distinction for presentation at The Liver Meeting 2017, held in Washington DC, October 20-24, 2017.

 

RECENT NEWS ON NVP022

SOME PUBLICATIONS RELATED WITH NVP022

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH NVP022


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE